Xenon Pharmaceuticals (XENE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
February 27, 2025 4:01 PM ESTPhase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch
First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year
Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year
Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025
Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor
Conference call at 4:30 pm ET today
VANCOUVER,... More
